Anpheros Search · Treatment

Histamine

Also known as: histamine dihydrochloride · Ceplene · 2nd CHANCE MOBILITY Pain Relief · AMINO ACTIVE Topical Analgesic Cream · Arthritis Pain Relief Cream · Australian Dream Back Pain · BAKERS BEST Arthritis Pain Relief Cream with Hemp and Lavender · Bakers Best Arthritis Pain Relief · Bakers Best Arthritis Pain Relief with Hemp Seed · Glucosamine Cream EXTRA STRENGTH

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, histamine dihydrochloride maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2, though its efficacy has not been fully demonstrated in patients older than age 60. In the United States, histamine dihydrochloride is indicated for use by adults and children over 12 years to be applied as a thin layer to the pain site and massaged until thoroughly absorbed into the skin, up to 3 to 4 times daily.

From: Source: European Medicines Agency (EMA), Ceplene — EPAR, 19/04/2023. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

EMA
EMEA/H/C/000796

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

FDA (USA) Arthritis Pain Relief Cream

Indications and Usage Section For use by adults and children over 12 years. Apply a thin layer to pain site and massage until thoroughly absorbed into skin. Apply no more than 3 to 4 times daily. Children 12 years or younger consult a physician.

Data provided by the U.S. Food and Drug Administration.

Document date: 20260521 · Official document →

EMA (EU) Ceplene

Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.

Source: European Medicines Agency (EMA), Ceplene — EPAR, 19/04/2023. © European Medicines Agency.

Document date: 19/04/2023 · Official document →

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Histamine approved for in the European Union?

Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60. (Source: European Medicines Agency (EMA), Ceplene — EPAR, 19/04/2023. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Data provided by the U.S. Food and Drug Administration.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Ceplene — EPAR, 19/04/2023. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →